Tens of Millions in Funding Raised: A Breakthrough in Ophthalmic Precision Manufacturing
Belle Healthcare
Microsurgical Instrument Design and Manufacturer
【Viewpoint · Ophthalmology Industry Navigation】
Major Events Monthly Report | Editor's Recommended Article
Winning Atlas· Centralized Procurement Scaling | Ophthalmic Optometry Column
As capital begins to reassess ophthalmic microsurgical instruments, the focus of attention is shifting from market size to manufacturing precision.
Recently,Belle Healthcare Technology Co., Ltd.("Abbreviation: Belle Healthcare")Announced the completion of a new roundTens of Millions of Yuan in FinancingThis round was led by PwC Capital with participation from DeepRock Venture Capital. The funds will mainly be used for the construction of an intelligent manufacturing center for microsurgical instruments, the implementation of ophthalmic smart devices and consumables projects, and the expansion of overseas market sales.
As one of the few specializedFull series of microsurgical instruments for ophthalmology, otolaryngology, etc.Belle Healthcare, a research and development enterprise, has established a complete product matrix in niche areas such as disposable sterile ophthalmic tweezers, retinal brushes, and ophthalmic puncture devices.The product line has covered the core instrument categories of ophthalmic microsurgery.。
Globally, the ophthalmic microsurgical instruments market has long been dominated by multinational corporations such as Alcon and Bausch + Lomb. In China, there is a significant structural gap in this field:Intense homogenization competition in the low-end product market, while the high-end precision equipment market is still dominated by imported brands.。
The approval of scalable products and capital recognition for Belle Healthcare marks a critical transition for Chinese enterprises in the field of ophthalmic precision manufacturing, moving from "substitution" to "independence." This round of financing is not only a capital event but also a window into observing the evolution of China's high-end medical device manufacturing capabilities.
# Scarcity of Micron-Level Processing Capability
The manufacturing challenges of microsurgical instruments are concentrated inMicron-level precision machining, special material processing, and surface modification technologyThree Major Fields. Taking the commonly used micro-scissors and micro-forceps in ophthalmic surgeries as examples, their blade precision needs to be controlled at the micron level, and they must possess specific mechanical properties and biocompatibility.
Belle Healthcare's establishment of a 100,000-level cleanroom and automated production line in Suzhou reflects the direction of technological breakthroughs by companies in China. Its self-developed production line adoptsIndustrial-grade Femtosecond Laser Processing Technology, this technology has advantages over traditional machining in terms of precision control and heat-affected zone control, and is especially suitable for the manufacture of ultra-precision instruments such as ophthalmic surgical knives.
From the perspective of technological evolution, companies in China areTransition from OEM Contract Manufacturing to Independent Process DevelopmentBelle Healthcare's founding team once provided OEM services for international brands, which helped them accumulate process know-how. The current focus of technological competition has shifted to process innovation and the establishment of quality control systems, which are the key investment directions for this round of financing.
# The Differentiated Path of Domestic Substitution
The ophthalmic microsurgery instruments market exhibits a typical "pyramid" structure:The top is dedicated instruments for complex surgeries., monopolized by international brands;The middle part is conventional microscopic instruments., the substitution of domestically produced products is proceeding;The base consists of fundamental instruments., with a high localization rate but thin profit margins.
The product strategy of Belle Healthcare reflectsEntering from the mid-to-high-endMarket positioning. Its disposable ophthalmic surgical knives, fundus instruments, and other products have been clinically applied in many well-known hospitals in China, reflecting that domestically produced instruments are technically feasible in specific niche areas. It is worth noting that the logic behind its product line extension followsFrom instruments to equipment, from consumables to systemsThe path is similar to the development trajectory of leading international companies.
From the perspective of clinical demand, the volume of ophthalmic surgeries in China maintains steady growth. According to data from the National Health Commission, it is estimated that over 5 million cataract surgeries will be performed nationwide in 2024, and the number of retinal disease surgeries is also rapidly increasing.The growth in the number of surgeries has led to a continuous demand for high-precision instruments., but at the same time, for the equipment'sStandardization, ReproducibilityHigher requirements have been proposed. The promotion of disposable microsurgical instruments is precisely the product to meet this demand.
# From Market Stories to Manufacturing Capability Validation
The lead investor of this financing round, PuHua Capital, has several successful investment cases in the medical device field. Its investment logic is shifting from the early "market share" orientation to the current"Manufacturing Capability and Process Innovation"Evaluation.
The case of Belle Healthcare shows that in highly specialized medical device segments, capital pays more attention to enterprises'Vertical Integration Capability. This includes:
Autonomous Controllability of Precision Manufacturing Processes
Integrity and Traceability of the Quality System
Efficiency of R&D and Clinical Needs Alignment
The follow-up investment by DeepRock Venture Capital further strengthenedTechnology-Driven InvestmentThe logic behind this is that the investment focus is on hard technology fields such as life sciences and equipment manufacturing. The investment in Belle Healthcare reflects capital's renewed recognition of the "precision manufacturing attributes" in the medical device sector.
In terms of the use of financing, the funds will be mainly used for the construction of intelligent manufacturing centers. This indicates that at the current stage,Capacity and Process Upgrades Take Priority Over Scale Expansion. This decision aligns with the characteristics of the ophthalmic device industry: clinical requirements for product consistency are higher, and scaled production must be based on stable quality control.
# Intelligence and Platformization of Microsurgery
Belle Healthcare's "Ophthalmic Intelligent Surgical Instruments and Equipment" in the research and development pipeline reveals an important development direction of the industry. Traditional microsurgical instruments are transitioning fromFrom Purely Mechanical Tools to Intelligent Assistance SystemsEvolution.
The trend of intelligence is reflected in two levels:
First,Sensorization of Surgical Instruments Themselves, by integrating modules such as force feedback and position sensing, to improve the accuracy and safety of the surgery;
Secondly,Platformization of Surgical Systems, integrating modules such as instruments, imaging, and navigation to form a complete surgical solution.
In terms of market size, the global ophthalmic surgical instruments market is expected to continue growing, but the growth momentum is shifting from traditional instruments toIntelligent and disposable productsTransfer. The intelligent equipment and consumables pipeline laid out by Belle Healthcare is a forward-looking response to this structural change.
The company also plans to expand its business horizontally into microsurgical fields such as neurosurgery and otorhinolaryngology. This expansion logic is based onTransferability of Precision Manufacturing Capabilities:The micron-level processing technology validated in the ophthalmology field also holds application value in other microsurgical areas. This development approach of "technology platformization" may become an effective path for niche market companies to break through market ceilings.
# Company Profile
Belle Healthcare Technology Co., Ltd. was established in 2017. Its brands, such as "Belle Yifeng" and "BiYin," cover a full range of ophthalmic and otologic microsurgical instruments. These products have entered top-tier hospitals in China, including Peking Union Medical College Hospital and Tongren Hospital, and are also exported overseas. The company has raised hundreds of millions of yuan in cumulative financing, owns 77+ patents, and holds FDA/CE certifications. It has built a 5,000-square-meter GMP workshop with Class 100,000 standards. Its goal is to break the monopoly of imported products and create a benchmark for "Made in China Quality" in microsurgery.
GOC2025
Ophthalmology Solutions Case
Ophthalmic Instruments Industry Research
Statement
Copyright Statement:The original manuscript of "Eye Future" is owned by Beijing Siyu Bot Technology Co., Ltd. Unauthorized reproduction, excerpting, or mirroring on other websites, official accounts, or commercial platforms is prohibited; for authorized reproduction, please contact the backend to obtain permission. This platform reserves the right to pursue legal responsibility for unauthorized full-text reproduction, content rewriting, or adaptation.
